Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-01-16
2007-01-16
Wehbé, Anne M. (Department: 1633)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007200, C435S007210, C435S325000
Reexamination Certificate
active
10141618
ABSTRACT:
The invention provides methods for determining a prognosis for survival for a cancer patient. One method involves (a) measuring a level of a TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) comparing the level of TUCAN in the sample to a reference level of TUCAN, wherein a low level of TUCAN in the sample correlates with increased survival of the patient. Another method involves (a) measuring a level of TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) classifying the patient as belonging to either a first or second group of patients, wherein the first group of patients having low levels of TUCAN is classified as having an increased likelihood of survival compared to the second group of patients having high levels of TUCAN.
REFERENCES:
patent: 6110691 (2000-08-01), Wang et al.
patent: WO 96/12016 (1996-04-01), None
patent: WO 99/40102 (1999-08-01), None
patent: WO 01/16170 (2000-09-01), None
patent: WO 01/00826 (2001-01-01), None
patent: WO 01/18042 (2001-03-01), None
patent: WO 01/22920 (2001-04-01), None
patent: WO 01/30813 (2001-05-01), None
patent: WO 01/30971 (2001-05-01), None
patent: WO 01/66690 (2001-09-01), None
patent: WO 01/72822 (2001-10-01), None
Sinicrope et al. (1999) Clin. Can. Res., vol. 5, 1973-1804.
Liu et al. (2001) Eur. J. Canc., vol. 37, 1104-1110.
Bertin et al., “Human CARD4 Protein Is a Novel CED=4/Apaf-1 Cell Death Family Member That Activates NF-kB,”Journal of Biological Chemistry274(19):12955-12958 (1999).
Chu et al., “A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis,”J. Biol. Chem. 276:9239-9245 (2001).
Damiano et al., “CLAN, a Novel Human CED-4-like Gene,”Genomics75:77-83 (2001).
Geddes et al., “Human CARD12 Is a Novel CED4/Apaf-1 Family Member That Induces Apoptosis,”Biochemical and Biophysical Research Communications284:77-82 (2001).
Hlaing et al., “Molecular cloning and characterization of DEFCAP-L and —S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins,”J. Biol. Chem. 276:9230-9238 (2001).
Hofmann and Bucher, “The CARD domain: a new apoptotic signalling motif,”TIBS22 (5) :155-156 (1997).
Kawasaki et al., “Inhibition of Apoptosis by Survivin Predicts Shorter Survival Rates in Colorectal Cancer,”Cancer Research58:5071-5074 (1998).
Kobe and Deisenhofer, “Proteins with Leucine-rich repeats,”Current Opinion in Structural Biology, 3 (5) :409-416 (1995).
Koonin and Aravind, “The NACHT family —a new group of predicted NTPases implicated in apoptosis and MHC transcription activation,”TIBS25 (5) :223-224 (2000).
Ogura et al., “Nod2, a Nod1/Apag-1 Family Member That Is Restricted to Monocytes and Activates NF-kB,”Journal of Biological Chemistry276 (7) :4812-4818 (2001).
Pathan et al., “TUCAN, an Antiapoptotic Caspase-associated Recruitment Domain Family Protein Overexpressed in Cancer,”J. Biol. Chem. 276:32220-32229 (2001).
Poyet et al., “Identification of Ipaf, a Human Caspaase-1-activating Protein Related to Apaf-1,”Journal of Biological Chemistry276:28309-28313 (2001).
Rychlewski et al., “Comparison of sequence profiles. Strategies for structural predictions using sequence information,”Protein Science9:232-241 (2000).
Stapleton et al., “The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization,”Nature Structural Biology6 (1) :44-49 (1999).
Tamm et al., “Expression and prognostic significance of IAP-family gene in human cancers and myeloid leukemias,”Clin. Cancer Res.6 (5) :1796-803 (2000).
GenBank: Accession No. AC007728, Jun. 7, 1999.
GenBank: Accession No. AC010968, Sep. 29, 1999.
GenBank: Accession No. AC016492, Dec. 10, 1999.
GenBank: Accession No. AC025758, Mar. 16, 2000.
GenBank: Accession No. AC026732, Mar. 24, 2000.
GenBank: Accession No. AF322184.1, Apr. 15, 2002.
GenBank: Accession No. AF331519.1, Feb. 4, 2001.
GenBank: Accession No. AQ534686, May 18, 1999.
GenBank: Accession No. AY026322.1, Feb. 21, 2001.
Bouchier-Hayes et al., “CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-kappa B activiation pathways,”J Biol Chem. 276(47):44069-44077 (2001).
Ferreira et al., “Expression of cIAP1, cIAP2 and XIAP in relation to prognosis and response to chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients,”Proceedings of the American Association for Cancer Research Annual Meeting42:358-359 (2001).
Huerta et al., “Downstream apoptosis effectors APAF-1 and CLARP are markedly reduced in colon cancer,”Gastroenterology120(5)(1):A63 2001.
Saleh et al., “Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia,”Appl. Immunohistochem Mol Morphol. 8(3):175-182 (2000).
Sinicrope et al., “Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas,”Clin Cancer Res. 5(7):1793-1804 (1999).
GenBank Accession No. AAB62572.
McDermottt Will & Emery LLP
The Burnham Institute
Wehbe Anne M.
LandOfFree
Methods for determining the prognosis for cancer patients... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining the prognosis for cancer patients..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining the prognosis for cancer patients... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3738035